Alzheimer's Association updates diagnostic criteria to include biomarkers for early-stage detection.

The Alzheimer's Association has released new diagnostic criteria for Alzheimer's, focusing on biomarkers of beta amyloid and tau proteins detected by lab tests or brain scans. This shift aims to diagnose the disease in its earliest stages, even before symptoms develop. Critics, however, express concerns about "diagnostic creep" driven by profit, as not all individuals with biomarkers will necessarily develop dementia.